Abstract
Background Atopic dermatitis (AD) arises from a complex interaction between an impaired epidermal barrier, environmental exposures, and the infiltration of Th1/Th2/Th17/Th22 T cells. Transcriptomic analysis has advanced understanding of gene expression in cells and tissues. However, molecular quantitation of cytokine transcripts does not predict the importance of a specific pathway in AD or cellular responses to different inflammatory stimuli.
Objective To understand changes in keratinocyte transcriptomic programmes in human cutaneous disease during development of inflammation and in response to treatment.
Methods We performed in silico deconvolution of the whole-skin transcriptome. Using co-expression clustering and machine learning tools, we resolved the gene expression of bulk skin (n=7 datasets, n=406 samples), firstly, into unsupervised keratinocyte immune response phenotypes and, secondly, into 19 cutaneous cell signatures of purified populations from publicly available datasets.
Results We identify three unique transcriptomic programmes in keratinocytes, KC1, KC2, KC17, characteristic to immune signalling from disease-associated helper T cells. We cross-validate those signatures across different skin inflammatory conditions and disease stages and demonstrate that the keratinocyte response during treatment is therapy dependent. Broad spectrum treatment with ciclosporin ameliorated the KC17 response in AD lesions to a non-lesional immunophenotype, without altering KC2. Conversely, the specific anti-Th2 therapy, dupilumab, reversed the KC2 immunophenotype.
Conclusion Our analysis of transcriptomic signatures in cutaneous disease biopsies reveals the complexity of keratinocyte programming in skin inflammation and suggests that the perturbation of a single axis of immune signal alone may be insufficient to resolve keratinocyte immunophenotype abnormalities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Wellcome Trust Sir Henry Dale Fellowship
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding declaration: This work was supported by the Medical Research Council (MRC) DTP PhD Scheme and iCASE partnership with Unilever (scheme no. MR/N014308/1). MEP is funded by Sir Henry Dale Fellowship, Wellcome Trust (Grant no. 10937/Z/15/Z). The authors declare they have no conflict of interest.
Conflict of interest: None declared by any author
Data Availability
All data available through GEO
Abbreviations
- AD
- Atopic dermatitis
- AD-AcL
- Lesional (acute) AD skin
- AD-ChL
- Lesional (chronic) AD skin
- AD-Les
- Lesional (acute or chronic) AD skin
- AD-Non
- Non-lesional AD skin
- CD4
- Cluster of differentiation 4
- CD8
- Cluster of differentiation 8
- DDC
- CD11c+ Dermal Dendritic Cell
- FDR
- False Discovery Rate
- GCRMA
- Gene Chip Robust Multiarray Averaging
- GO
- Gene Ontology
- GOBP
- Gene Ontology, Biological Process
- HH
- Healthy
- IFN
- Interferon
- IL-1
- Interleukin-1
- IL-13
- Interleukin-13
- IL-17
- Interleukin-17
- IL-22
- Interleukin-22
- IL-26
- Interleukin-26
- IL-4
- Interleukin-4
- IL4Rα
- Interleukin-4 Receptor, alpha subunit
- KC
- Keratinocytes
- KC1
- Keratinocyte transcriptomic programme to type 1 inflammation
- KC17
- Keratinocyte transcriptomic programme to type 17 inflammation
- KC2
- Keratinocyte transcriptomic programme to type 2 inflammation
- KC22
- Keratinocyte transcriptomic programme to type 22 inflammation
- KFG
- Keratinocyte Growth Factor
- KRT6A
- Keratin 6A gene
- KRT6B
- Keratin 6B gene
- LC
- Langerhans Cell
- LIMMA
- Linear Models for Microarray Data
- MCL
- Markov Clustering algorithm
- Ps-Les
- Lesional psoriatic skin
- Ps-Non
- Non-lesional psoriatic skin
- S100
- S100 protein family gene
- SCORAD
- SCORing AD index
- SCORAD50
- 50% improvement in baseline SCORAD index
- SERPIN
- Serine protease inhibitor family gene
- Th1
- Type 1 inflammation
- Th17
- Type 17 inflammation
- Th2
- Type 2 inflammation
- Th22
- Type 22 inflammation
- TNF
- Tumour Necrosis Factor